Log In
BCIQ
Print this Print this
 

MM-141

  Manage Alerts
Collapse Summary General Information
Company Merrimack Pharmaceuticals Inc.
DescriptionTetravalent bispecific antibody targeting insulin-like growth factor 1 (IGF-1) receptor (IGF1R; CD221) and erb-b2 receptor tyrosine kinase 3 (ERBB3; HER3; EGFR3)
Molecular Target Erb-b2 receptor tyrosine kinase 3 (ERBB3) (HER3) (EGFR3) ; Insulin-like growth factor-1 (IGF-1) receptor (IGF1R) (CD221)
Mechanism of ActionBispecific antibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today